In this study the investigators are aiming to treat patients with acute heart failure with or without diabetes with Empagliflozin or placebo. Given the beneficial effects of Empagliflozin on heart failure hospitalization in the EMPA-REG OUTCOME trial, the investigators do expect a similar beneficial effect to be present in patients with acute heart failure. Acute heart failure is a state of hydropic decompensation resulting in dyspnea and congestions, caused by different etiologies of cardiac disease. Recompensation is reached by application of diuretic drugs and fluid restriction.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥ 18 years
✓. Patients with acute heart failure with associated signs or symptoms (dyspnea on exertion, orthopnea, paroxysmal dyspnea, peripheral oedema, chest x-ray with pulmonary congestion)
✓. Serum levels of NT-proBNP ≥ 1000 pg/ml within 48 hours of Informed Consent
✓. Written informed consent prior to study participation
Exclusion criteria
✕. Type 1 diabetes
✕. Participants of child-bearing age without adequate contraception
✕. Pregnancy or lactating females
✕. Cardiogenic shock
✕. Acute coronary syndrome within 30 days prior to randomization
✕. Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization
What they're measuring
1
effect of Empagliflozin 10mg qd versus placebo on cardiac output in patients with acute heart failure